Triglyceride-Glucose Index in Diabetic Nephropathy in Type 2diaberes Mellitus Patients
Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05602532
Collaborator
(none)
100
11
Study Details
Study Description
Brief Summary
The aim of the present study is to investigate the associations between the TyG index and diabetic nephropathy in patients with type2 DM .
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
the triglyceride-glucose (TyG) index was proposed as a simple and reliable surrogate marker of IR, and it has been reported to be closely correlated with the HOMA-IR index. The TyG index has the advantage of being applicable in clinical practice since both triglyceride and glucose levels are routinely measured and the cost of these measurements is low.
Study Design
Study Type:
Observational
Anticipated Enrollment
:
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Triglyceride-Glucose Index in Diabetic Nephropathy in Type 2diaberes Mellitus Patients
Anticipated Study Start Date
:
Nov 1, 2022
Anticipated Primary Completion Date
:
Nov 1, 2022
Anticipated Study Completion Date
:
Oct 1, 2023
Outcome Measures
Primary Outcome Measures
- TyG index in type 2diaberes Mellitus [Baseline]
Detecting the association between the TyG index and diabetic nephropathy in type 2 diabetes
Eligibility Criteria
Criteria
Ages Eligible for Study:
25 Years
to 75 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
- patients with type 2 DM
Exclusion Criteria:
- (1) Individuals with obstructive uropathy, severe heart failure, stroke, liver disease, cancer, autoimmune disease (2) Pregnant woman. (3)End stage renal disease patients on dialysis ( glomerular filtration rate <15 mL/min/1.73 m2) or renal transplantation.
(4) Type 1 Diabetic patient. (5) Albuminuria due to non-diabetic renal disease
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002 May 15;287(19):2570-81. doi: 10.1001/jama.287.19.2570.
- Lee MY, Hsiao PJ, Huang JC, Hsu WH, Chen SC, Chang JM, Shin SJ. ASSOCIATIONS BETWEEN TRIGLYCERIDE/HIGH-DENSITY LIPOPROTEIN CHOLESTEROL RATIO AND MICRO- AND MACROANGIOPATHIES IN TYPE 2 DIABETES MELLITUS. Endocr Pract. 2018 Jul;24(7):615-621. doi: 10.4158/EP-2017-0254.
- Liang S, Cai GY, Chen XM. Clinical and pathological factors associated with progression of diabetic nephropathy. Nephrology (Carlton). 2017 Dec;22 Suppl 4:14-19. doi: 10.1111/nep.13182.
- Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11(18):2279-99. doi: 10.2174/1381612054367300.
- Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018 Feb;14(2):88-98. doi: 10.1038/nrendo.2017.151. Epub 2017 Dec 8.
Responsible Party:
Aya Abo Elyosr Garhey Yonis,
Doctor,
Assiut University
ClinicalTrials.gov Identifier:
NCT05602532
Other Study ID Numbers:
- TYG index in DN in type 2 DM
First Posted:
Nov 2, 2022
Last Update Posted:
Nov 2, 2022
Last Verified:
Oct 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: